COVID-19 patients have increased levels of pro-inflammatory effector cytokines, such as tumor necrosis factor alpha (TNFα), interleukin (IL)-1B, and IL-6, as well as chemokines, such as CCL2 and CXCL10, especially in those who are critically ill [22–25]. This evidence concerns the gene IL6 and COVID-19.